M L Dahl

Functional polymorphism in the alcohol dehydrogenase 3 (ADH3) promoter.

M Ingelman-Sundberg, M. Ingelman-Sundberg, J. Höög, 2001, Pharmacogenetics.

Quick onset of severe abdominal pain after codeine in an ultrarapid metabolizer of debrisoquine.

M. Dahl, F. Sjöqvist, M L Dahl, 1997, Therapeutic drug monitoring.

Moving toward genetic profiling in patient care: the scope and rationale of pharmacogenetic/ecogenetic investigation.

M Ingelman-Sundberg, M. Ingelman-Sundberg, L. Bertilsson, 2001, Drug metabolism and disposition: the biological fate of chemicals.

D2 dopamine receptor occupancy during low-dose treatment with haloperidol decanoate.

C. Halldin, L. Farde, L. Bertilsson, 1995, The American journal of psychiatry.

Evaluation of caffeine as an in vivo probe for CYP1A2 using measurements in plasma, saliva, and urine.

C. Alm, L. Bertilsson, M. Dahl, 2000, Therapeutic drug monitoring.

Debrisoquine and S-mephenytoin hydroxylation phenotypes and genotypes in a Korean population.

M Ingelman-Sundberg, M. Ingelman-Sundberg, L. Bertilsson, 1996, Pharmacogenetics.